Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China
Compared with sorafenib, toripalimab plus bevacizumab is likely a cost-effective first-line treatment option for advanced HCC in China.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0000-0003-1880-5096)
- Jing He (ORCID: https://orcid.org/0009-0000-5081-6954)
- Kai Ma (ORCID: https://orcid.org/0009-0002-1697-665X)
Institutions
- University of Electronic Science and Technology of China (CN)
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1676293
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00